Foghorn Therapeutics Inc.
FHTX
Positions held
Your positionsFHTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $118.18M | Enterprise value | -$6.30M | Trailing P/E | — | Forward P/E | -1.94 |
| PEG | — | Price / book | -1.44 | Beta | 3.01 | Dividend yield | 0.00% |
| Revenue growth | 112.7% | Earnings growth | — | Gross margin | -114.6% | Operating margin | -54.8% |
| Profit margin | -1.8% | ROE | — | ROA | -19.9% | Debt / equity | — |
| Current ratio | 3.36 | Free cash flow | -$51.95M | Analyst recommendation | buy | Mean target | $6.00 |
| 52w high | $7.61 | 52w low | $1.79 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $16.1M | $3.3M | $9.2M | $8.2M | $7.6M | — |
| Op margin | -54.8% | -660.3% | -211.9% | -226.9% | -279.2% | — |
| Net income | -$7.2M | -$19.9M | -$21.7M | -$15.8M | -$17.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.8M | -$21.6M | -$19.6M | -$18.5M | -$21.1M | — |
- Revenue +392% vs prior quarter ($16M vs $3.3M).
- Operating margin expanded to -54.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | — |
| Op margin | -265.6% | -443.7% | -315.9% | -609.2% | — |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$109M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$82.1M | -$100M | -$108M | -$117M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Foghorn Therapeutics Shares Fall After Wedbush Downgrade
2026-10-02 · Top Midday Decliners
2026-10-02 · FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
2026-10-02 · Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
2026-10-02 · Correction: Top Midday Decliners
2026-10-02 · Wedbush Downgrades Foghorn Therapeutics to Neutral From Outperform, Cuts Price Target to $2 From $10
2026-10-02 · TD Cowen Downgrades Foghorn Therapeutics to Hold From Buy
2026-10-02 · BTIG Downgrades Foghorn Therapeutics to Neutral From Buy
2026-10-01 · Sector Update: Healthcare Stocks Fall Late Afternoon
2026-10-01 · Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
2026-10-01 · Sector Update: Healthcare
2026-10-01 · Top Midday Decliners
Price (daily)
Full chart · RSI · MACD · patterns